Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BHP Early Infant Treatment Study: A Clinical Treatment Trial of HIV+ Infants in Botswana

Next Previous
X
Search
Trial Profile

BHP Early Infant Treatment Study: A Clinical Treatment Trial of HIV+ Infants in Botswana

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 21 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lamivudine (Primary) ; Lopinavir/ritonavir (Primary) ; Nevirapine (Primary) ; Zidovudine (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms EIT Study

    • Most Recent Events

    • 17 Oct 2022 Planned End Date changed from 1 May 2022 to 30 Jun 2029.
    • 03 Aug 2021 New trial record
    • 28 Jul 2021 Results of an analysis from EIT cohort Botswana in infants (n=27) and maternal plasma genotyping (n=22) assessing occurrence of HIV drug resistance mutation in both intact and defective HIV-1 cell-associated DNA among early-treated infants published in the AIDS

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top